No replies to this topic

[Zico_Lonvi]

Hello everyone,

We’ve recently posted two preprints on PCC1 (Procyanidin C1), a grape-seed–derived trimeric polyphenol with senotherapeutic properties.

Review (mechanistic & multi-organ data)

Procyanidin C1: A Natural Dual-Mode Senotherapeutic for Pan-Organ Senescence Modulation and Clearance
https://doi.org/10.2...v1<span></span>

• Summarizes PCC1’s dual mechanism (low-dose senomorphic vs. high-dose senolytic)

• Covers pan-organ efficacy (retina, brain, lung, kidney, skin, hematopoietic/immune systems)

• Compares PCC1’s safety/tolerability with first-generation senolytics

Human pilot study (first-in-humans, n=17)

PCC1 Senolytic Complex Compound's Preliminary Study on Regulating Cellular Senescence
https://doi.org/10.5...62<span></span>

• 3-day oral PCC1 complex (435 mg ×3/day) in elderly (50–86 yrs)

• By Day-5:
  • p21 ↓ ~45–60%
  • SA-β-Gal ↓ ~32–42%
  • SASP cytokines (IL-6, IL-8, VEGF, TGF-β1) ↓ 30–70%

• No adverse events observed

Why we think this matters

• PCC1 works at milligram doses in days, vs. other natural senolytics like fisetin or quercetin that require gram doses for weeks.

• Early evidence suggests a wider safety margin than D+Q or Navitoclax.

• Could represent a new senolytic class suitable for nutritional/translational use.

We’re sharing these here to invite feedback, critical discussion, and collaboration ideas from the Longecity community.

Both preprints are open-access and citable.